

Richard B Warren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3793200/publications.pdf>

Version: 2024-02-01

245
papers

10,713
citations

31949

53
h-index

42364

92
g-index

260
all docs

260
docs citations

260
times ranked

10309
citing authors

#	ARTICLE	IF	CITATIONS
1	Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)*. <i>British Journal of Dermatology</i> , 2022, 186, 245-256.	1.4	22
2	Differences in Clinical Features and Comorbid Burden between HLA-C*06:02 Carrier Groups in >9,000 People with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1617-1628.e10.	0.3	11
3	Depression and Suicidality in Patients With Psoriasis and the Role of Psoriatic Arthritis: A Cross-sectional Study in a Tertiary Setting. <i>Journal of the Academy of Consultation-Liaison Psychiatry</i> , 2022, 63, 372-383.	0.2	12
4	Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. <i>Dermatology and Therapy</i> , 2022, 12, 561-575.	1.4	7
5	Clinical Disease Measures in Generalized Pustular Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 39-50.	3.3	25
6	Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. <i>British Journal of Dermatology</i> , 2022, 187, 254-256.	1.4	11
7	Paradoxical eczema in patients with psoriasis receiving biologics: a case series. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 1174-1178.	0.6	8
8	Remote consultations: an audit of the management of dermatology patients on biologics during the first wave of the COVID-19 pandemic. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2697-2697.	1.1	1
9	A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17. <i>Dermatology and Therapy</i> , 2022, 12, 787-800.	1.4	6
10	Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis. <i>Advances in Therapy</i> , 2022, 39, 2256-2269.	1.3	10
11	Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 855-865.	1.3	11
12	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 561.	2.0	12
13	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study. <i>Efficacy and Mechanism Evaluation</i> , 2022, 9, 1-106.	0.9	1
14	A rapid access clinic for psoriasis: first experiences. <i>British Journal of Dermatology</i> , 2022, 187, 426-428.	1.4	2
15	Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE 2 and 3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1275-1283.	1.3	8
16	Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 735.	2.0	22
17	Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 882-893.	1.5	21
18	Secukinumab improves the quality of life of family members and partners of people with psoriasis: Family Dermatology Life Quality Index (FDLQI) results from a randomised open-label study (SIGNATURE). <i>Journal of Clinical Investigation</i> , 2022, 1, 207-218.		0

#	ARTICLE	IF	CITATIONS
19	Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2022, 12, 1777-1792.	1.4	22
20	Risk of hospitalization and death due to infection in people with psoriasis: a population-based cohort study using the Clinical Practice Research Datalink*. <i>British Journal of Dermatology</i> , 2021, 184, 78-86.	1.4	26
21	Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. <i>British Journal of Dermatology</i> , 2021, 184, 640-651.	1.4	16
22	Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial*. <i>British Journal of Dermatology</i> , 2021, 184, 50-59.	1.4	119
23	An evaluation of dermatology patients shielding during the COVID-19 outbreak. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 193-194.	0.6	4
24	Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis – time for a paradigm change. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 824-834.	1.3	48
25	Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). <i>British Journal of Dermatology</i> , 2021, 184, 652-662.	1.4	15
26	Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 450-457.	1.3	14
27	Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: <i>post hoc</i> analysis through 64 weeks from reSURFACE 1 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 919-927.	1.3	15
28	Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 60-71.	1.5	136
29	Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre. <i>Dermatology and Therapy</i> , 2021, 11, 149-160.	1.4	18
30	Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1269-1277.	0.6	38
31	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , 2021, 397, 487-498.	6.3	139
32	Editorial: fixed-dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 3-4.	1.3	0
33	Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 35-41.	1.3	12
34	Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values 1, 2, 3 or 5 derived from a statistical conversion method. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1161-1175.	1.3	13
35	Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey*. <i>British Journal of Dermatology</i> , 2021, 185, 80-90.	1.4	26
36	POS1022...BIMEKIZUMAB SAFETY AND EFFICACY IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM A PHASE 2b OPEN-LABEL EXTENSION STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 779-780.	0.5	5

#	ARTICLE	IF	CITATIONS
37	POS1042â€¦EFFICACY AND SAFETY OF DELUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETIK PSO-1 STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 795.1-796.	0.5	21
38	Risk of COVIDâ€19 infection in adult patients with atopic eczema and psoriasis: a singleâ€centre crossâ€sectional study. <i>British Journal of Dermatology</i> , 2021, 185, 441-443.	1.4	13
39	Fiveâ€year efficacy and safety of tildrakizumab in patients with moderateâ€toâ€severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*. <i>British Journal of Dermatology</i> , 2021, 185, 323-334.	1.4	55
40	Defining trajectories of response in patients with psoriasis treated with biologic therapies. <i>British Journal of Dermatology</i> , 2021, 185, 825-835.	1.4	4
41	Antibody responses to singleâ€dose SARSâ€CoVâ€2 vaccination in patients receiving immunomodulators for immuneâ€mediated inflammatory disease. <i>British Journal of Dermatology</i> , 2021, 185, 646-648.	1.4	30
42	Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BEâVIVID and BEâREADY Phaseâ3 Trials. <i>Dermatology and Therapy</i> , 2021, 11, 1551-1569.	1.4	4
43	Bimekizumab versus Adalimumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021, 385, 130-141.	13.9	114
44	Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINEâ€2 and AMAGINEâ€3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2034-2044.	1.3	6
45	Bimekizumab versus Secukinumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021, 385, 142-152.	13.9	173
46	Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics. <i>Dermatology and Therapy</i> , 2021, 11, 1657-1665.	1.4	3
47	Chromatin Looping Links Target Genes with Genetic Risk Loci for Dermatological Traits. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1975-1984.	0.3	19
48	Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy Showcase. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1872-1878.	0.3	4
49	Describing the burden of the COVIDâ€19 pandemic in people with psoriasis: findings from a global crossâ€sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e636-e640.	1.3	18
50	Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1073-1081.	1.3	5
51	Threeâ€year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2398-2408.	1.3	4
52	Enhanced NF-ÎB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. <i>Nature Communications</i> , 2021, 12, 4741.	5.8	23
53	Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial. <i>Advances in Therapy</i> , 2021, 38, 5253-5269.	1.3	5
54	Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis. <i>JAMA Dermatology</i> , 2021, 157, 66.	2.0	14

#	ARTICLE	IF	CITATIONS
55	Assessing the Quality and Coherence of Network Meta-Analyses of Biologics in Plaque Psoriasis: What Does All This Evidence Synthesis Tell Us?. <i>Dermatology and Therapy</i> , 2021, 11, 181-220.	1.4	8
56	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	2.8	86
57	Psoriasis and Comorbidities. , 2021, , 363-397.		0
58	Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models. <i>Scientific Reports</i> , 2021, 11, 23335.	1.6	10
59	Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks. <i>British Journal of Dermatology</i> , 2020, 182, 605-617.	1.4	103
60	Secukinumab for patients failing previous tumour necrosis factor inhibitor therapy: results of a randomized open-label study (SIGNATURE). <i>British Journal of Dermatology</i> , 2020, 183, 60-70.	1.4	21
61	Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 769-778.	1.3	27
62	Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Therapeutics Update). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1161-1173.	1.3	32
63	Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses. <i>Dermatology and Therapy</i> , 2020, 10, 73-86.	1.4	38
64	Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. <i>Quality of Life Research</i> , 2020, 29, 369-380.	1.5	2
65	Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1138-1149.	0.6	37
66	Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1161-1173.	1.3	32
67	Risankizumab vs. adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal. <i>British Journal of Dermatology</i> , 2020, 183, 220-221.	1.4	1
68	PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis. <i>Advances in Therapy</i> , 2020, 37, 4730-4753.	1.3	6
69	Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease. <i>American Journal of Human Genetics</i> , 2020, 107, 539-543.	2.6	44
70	Update on risankizumab for the treatment of moderate to severe psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1245-1251.	1.4	5
71	Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. <i>JAMA Dermatology</i> , 2020, 156, 1216.	2.0	18
72	Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis. <i>Dermatology and Therapy</i> , 2020, 10, 1255-1272.	1.4	6

#	ARTICLE	IF	CITATIONS
73	Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases. <i>JAMA Dermatology</i> , 2020, 156, 787.	2.0	45
74	Mapping DNA interaction landscapes in psoriasis susceptibility loci highlights KLF4 as a target gene in 9q31. <i>BMC Biology</i> , 2020, 18, 47.	1.7	19
75	Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic. <i>British Journal of Dermatology</i> , 2020, 183, 792-794.	1.4	58
76	Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). <i>British Journal of Dermatology</i> , 2020, 183, 294-302.	1.4	85
77	Progress to Date in Advancing Stratified Medicine in Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 619-626.	3.3	9
78	The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1695-1706.	1.3	57
79	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020, 395, 427-440.	6.3	122
80	Ixekizumab for the treatment of psoriasis: up-to-date. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 549-557.	1.4	39
81	Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. <i>Clinical and Translational Science</i> , 2020, 13, 400-409.	1.5	9
82	Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1440-1448.	1.3	47
83	Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. <i>British Journal of Dermatology</i> , 2020, 183, 404-406.	1.4	18
84	How is safety of dermatology drugs assessed: trials, registries, and spontaneous reporting. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 449-457.	1.0	5
85	Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2129-2137.	0.3	6
86	A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial. <i>Trials</i> , 2020, 21, 158.	0.7	7
87	Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>British Journal of Dermatology</i> , 2019, 180, 329-337.	1.4	36
88	Clinical and genetic differences between pustular psoriasis subtypes. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1021-1026.	1.5	165
89	Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. <i>PLoS ONE</i> , 2019, 14, e0220868.	1.1	118
90	Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis. <i>JAMA Dermatology</i> , 2019, 155, 1235.	2.0	30

#	ARTICLE	IF	CITATIONS
91	Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 699-709.	3.3	5
92	Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1676-1684.	1.3	64
93	Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e352-e353.	1.3	3
94	The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature. <i>Dermatology and Therapy</i> , 2019, 9, 373-381.	1.4	2
95	A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. <i>British Journal of Dermatology</i> , 2019, 181, 1265-1271.	1.4	15
96	Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways. <i>British Journal of Dermatology</i> , 2019, 181, 859-862.	1.4	7
97	A Summary of 2018 and What Lies Ahead for Dermatology and Therapy in 2019. <i>Dermatology and Therapy</i> , 2019, 9, 1-3.	1.4	1
98	Long-term, real-world efficacy of biologics for psoriasis: a single centre's experience. <i>British Journal of Dermatology</i> , 2019, 181, 599-601.	1.4	4
99	HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2120-2130.	1.5	128
100	Long-term safety of adalimumab in adult patients with plaque psoriasis. <i>British Journal of Dermatology</i> , 2019, 180, e13-e13.	1.4	1
101	OP0108...DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAÏVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY. , 2019, , .		6
102	FRI0004...CHROMATIN INTERACTIONS IN NOVEL CELL TYPES REVEAL PARK7 AND ERRF1 AS PUTATIVE CAUSAL GENES IN THE SUSCEPTIBILITY TO PSORIATIC ARTHRITIS. , 2019, , .		0
103	Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2019, 180, 76-85.	1.4	23
104	Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. <i>British Journal of Dermatology</i> , 2019, 180, 1069-1076.	1.4	74
105	Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. <i>Journal of Investigative Dermatology</i> , 2019, 139, 115-123.	0.3	60
106	Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. <i>British Journal of Dermatology</i> , 2019, 180, 894-901.	1.4	12
107	Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. <i>British Journal of Dermatology</i> , 2019, 181, 256-264.	1.4	14
108	A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis. <i>Journal of Investigative Dermatology</i> , 2019, 139, 100-107.	0.3	30

#	ARTICLE	IF	CITATIONS
109	Brodalumab in psoriasis: evidence to date and clinical potential. <i>Drugs in Context</i> , 2019, 8, 1-11.	1.0	61
110	Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. <i>British Journal of Dermatology</i> , 2018, 178, 1064-1071.	1.4	43
111	Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1530-1534.	1.3	11
112	Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2018, 138, 775-784.	0.3	71
113	Genotypic variability-based genome-wide association study identifies non-additive loci HLA-C and IL12B for psoriasis. <i>Journal of Human Genetics</i> , 2018, 63, 289-296.	1.1	9
114	Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. <i>JAMA Dermatology</i> , 2018, 154, 581.	2.0	74
115	Guselkumab for psoriasis: a critical appraisal of Phase III studies. <i>Immunotherapy</i> , 2018, 10, 67-75.	1.0	4
116	Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2018, 138, 534-541.	0.3	62
117	Impact of Disease Severity, Illness Beliefs, and Coping Strategies on Outcomes in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 295-302.	1.5	22
118	Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 3-14.	1.3	76
119	A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. <i>Trials</i> , 2018, 19, 465.	0.7	15
120	What's new in psoriasis treatment? An analysis of systematic reviews published in 2015. <i>Clinical and Experimental Dermatology</i> , 2018, 43, 759-765.	0.6	5
121	Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2178-2184.	1.3	8
122	Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. <i>British Journal of Dermatology</i> , 2018, 179, 1205-1207.	1.4	69
123	Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2200-2207.	1.3	42
124	Ustekinumab for the treatment of psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018, 37, 143-147.	1.6	12
125	Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 405-411.	3.3	24
126	Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 879-881.	1.4	26

#	ARTICLE	IF	CITATIONS
127	Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1646-1654.	0.3	108
128	British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. <i>British Journal of Dermatology</i> , 2017, 177, 628-636.	1.4	226
129	Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate to severe psoriasis patients: 12-week results from two Phase 3 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1867-1875.	1.3	12
130	Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 1410-1421.	1.4	24
131	Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate to severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (<sc>UNCOVER</sc>â€1, <sc>UNCOVER</sc>â€2 and <sc>UNCOVER</sc>â€3). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1686-1692.	1.3	60
132	Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study. <i>British Journal of Dermatology</i> , 2017, 177, 828-836.	1.4	18
133	A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). <i>British Journal of Dermatology</i> , 2017, 177, 197-205.	1.4	36
134	Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 441-448.e2.	0.6	86
135	The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 243-249.	1.9	6
136	An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 528-537.	6.3	94
137	Reply to "Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials": reply from the authors. <i>British Journal of Dermatology</i> , 2017, 177, 1766-1767.	1.4	2
138	Research Techniques Made Simple: Bioinformatics for Genome-Scale Biology. <i>Journal of Investigative Dermatology</i> , 2017, 137, e163-e168.	0.3	14
139	Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1774-1779.	0.5	51
140	Re: Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2644-2646.	0.3	7
141	Raising Standards for the Evaluation of Future Psoriasis Therapeutics: A Critical Checklist. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 642-648.	2.3	2
142	Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2017, 176, 890-901.	1.4	107
143	Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>British Journal of Dermatology</i> , 2017, 176, 1297-1307.	1.4	50
144	Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. <i>Human Molecular Genetics</i> , 2017, 26, 4301-4313.	1.4	41

#	ARTICLE	IF	CITATIONS
145	AB0115â€¦Comparison of the bacterial stool microbiota in established psoriatic arthritis (PSA) and psoriasis (PSC) - exploratory analysis of pilot data. , 2017, , .		0
146	Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. British Journal of Dermatology, 2016, 175, 487-492.	1.4	114
147	Novel Oral Therapies for Psoriasis and Psoriatic Arthritis. American Journal of Clinical Dermatology, 2016, 17, 191-200.	3.3	34
148	Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis. Journal of Investigative Dermatology, 2016, 136, 1584-1591.	0.3	63
149	British Association of Dermatologistsâ€™ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. British Journal of Dermatology, 2016, 175, 23-44.	1.4	86
150	Early- and late-onset psoriasis: a cross-sectional clinical and immunocytochemical investigation. British Journal of Dermatology, 2016, 175, 1038-1044.	1.4	33
151	The risk of postâ€“operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 86-91.	1.3	24
152	AB0727â€¦Increased Rates of Hypertension in Patients with Psoriatic Arthritis Compared To Psoriasis Alone: Results from The UK Biobank: Table 1.. Annals of the Rheumatic Diseases, 2016, 75, 1153.1-1153.	0.5	1
153	Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. Drug Safety, 2016, 39, 755-762.	1.4	112
154	A novel mutation in <sc>IL</sc>36<sc>RN</sc> underpins childhood pustular dermatosis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 302-305.	1.3	15
155	Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis. Archives of Dermatological Research, 2016, 308, 201-205.	1.1	35
156	One SNP at a Time: Moving beyond GWAS in Psoriasis. Journal of Investigative Dermatology, 2016, 136, 567-573.	0.3	48
157	A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis. Dermatology and Therapy, 2016, 6, 1-12.	1.4	118
158	Effectiveness of Subcutaneous Methotrexate in Chronic Plaque Psoriasis. Journal of Drugs in Dermatology, 2016, 15, 345-9.	0.4	6
159	Demographics and disease characteristics of patients with psoriasis enrolled in the <sc>B</sc>ritish <sc>A</sc>ssociation of <sc>D</sc>ermatologists <sc>B</sc>iologic <sc>I</sc>nterventions <sc>R</sc>egister. British Journal of Dermatology, 2015, 173, 510-518.	1.4	87
160	Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2015, 135, 2632-2640.	0.3	318
161	Establishing an Academicâ€“Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy. Journal of Investigative Dermatology, 2015, 135, 2903-2907.	0.3	30
162	Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV , multicenter, randomized, controlled, prospective study. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1156-1163.	1.3	20

#	ARTICLE	IF	CITATIONS
163	Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes. <i>Journal of Dermatological Treatment</i> , 2015, 26, 329-334.	1.1	11
164	Efficacy and safety of emerging immunotherapies in psoriasis. <i>Immunotherapy</i> , 2015, 7, 119-133.	1.0	18
165	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. <i>Lancet, The</i> , 2015, 385, S48.	6.3	18
166	Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2011-2019.	2.9	90
167	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nature Communications</i> , 2015, 6, 6046.	5.8	149
168	Pharmacogenomics and the Resulting Impact on Psoriasis Therapies. <i>Dermatologic Clinics</i> , 2015, 33, 149-160.	1.0	13
169	Identification of loci associated with late-onset psoriasis using dense genotyping of immune-related regions. <i>British Journal of Dermatology</i> , 2015, 172, 933-939.	1.4	17
170	Polymorphisms in IL-1B Distinguish between Psoriasis of Early and Late Onset. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1459-1462.	0.3	26
171	Development of chronic inflammatory demyelinating polyneuropathy in a patient receiving infliximab for psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 206-209.	1.4	9
172	Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools. <i>Arthritis Care and Research</i> , 2014, 66, 1410-1416.	1.5	21
173	Psoriatic arthritis screening tools: study design and methodologic challenges - reply from authors. <i>British Journal of Dermatology</i> , 2014, 170, 995-996.	1.4	0
174	Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. <i>British Journal of Dermatology</i> , 2014, 171, 485-491.	1.4	32
175	A case of CD8+ small/medium-sized pleomorphic T-cell lymphoma: clinical and histopathological differential diagnosis. <i>British Journal of Dermatology</i> , 2014, 170, 204-206.	1.4	4
176	Genotyping of immune-related genetic variants identifies <i>TYK2</i> as a novel associated locus for idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1750-1752.	0.5	25
177	The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. <i>Rheumatology</i> , 2014, 53, 213-222.	0.9	177
178	Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis. <i>Journal of Dermatological Treatment</i> , 2014, 25, 61-62.	1.1	1
179	Treating moderate to severe psoriasis - best use of biologics. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 269-279.	1.3	24
180	A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 438-453.	1.3	122

#	ARTICLE	IF	CITATIONS
181	The spectrum of oculocutaneous disease. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 795.e1-795.e25.	0.6	20
182	The spectrum of oculocutaneous disease. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 821.e1-821.e19.	0.6	11
183	SAT0052â€¦Influence of Immunogenicity and Drug Levels on the Efficacy of Long-Term Treatment of Rheumatoid Arthritis with Adalimumab and Etanercept: A Uk-Based Prospective Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 608.1-608.	0.5	7
184	Barriers to the prescription of systemic therapies for moderate-to-severe psoriasisâ€“â€“a multinational cross-sectional study. <i>Archives of Dermatological Research</i> , 2013, 305, 899-907.	1.1	48
185	National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines. <i>Archives of Dermatological Research</i> , 2013, 305, 637-643.	1.1	7
186	Expression of microRNAâ€“184 in keratinocytes represses argonaute 2. <i>Journal of Cellular Physiology</i> , 2013, 228, 2314-2323.	2.0	39
187	Dermatology: Future Therapeutic Perspectives. <i>Dermatology and Therapy</i> , 2013, 3, 115-116.	1.4	0
188	Psoriasis and susceptibility to other autoimmune diseases: an outline for the clinician. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 99-101.	1.3	9
189	An investigation of rheumatoid arthritis loci in patients with early-onset psoriasis validates association of the <i>REL</i> gene. <i>British Journal of Dermatology</i> , 2013, 168, 864-866.	1.4	11
190	Ustekinumab for psoriatic arthritis: close to the PSUMMIT?. <i>Lancet, The</i> , 2013, 382, 748-749.	6.3	2
191	Cutaneous <i>Mycobacterium haemophilum</i> infection in a patient receiving infliximab for psoriasis. <i>British Journal of Dermatology</i> , 2013, 168, 446-447.	1.4	11
192	Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.4	130
193	Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2340-2346.	0.3	224
194	Time for a â€“jointâ€“ approach?. <i>British Journal of Dermatology</i> , 2013, 168, 683-684.	1.4	7
195	Treatment of severe psoriasis with biological therapies in patients with viral hepatitis B and C. <i>British Journal of Dermatology</i> , 2013, 168, 461-462.	1.4	3
196	Patients' Narratives. <i>Current Problems in Dermatology</i> , 2013, 44, 145-157.	0.8	3
197	Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1350-1354.	0.5	39
198	Emerging Therapies for the Treatment of Psoriasis. <i>Dermatology and Therapy</i> , 2012, 2, 16.	1.4	11

#	ARTICLE	IF	CITATIONS
199	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. <i>Nature Genetics</i> , 2012, 44, 1341-1348.	9.4	848
200	Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. <i>British Journal of Dermatology</i> , 2012, 166, 189-195.	1.4	34
201	Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. <i>British Journal of Dermatology</i> , 2012, 166, 474-482.	1.4	59
202	The British Association of Dermatologistsâ€™ Biologic Interventions Register (BADBIR): design, methodology and objectives. <i>British Journal of Dermatology</i> , 2012, 166, 545-554.	1.4	108
203	In search of oral psoriasis. <i>Archives of Dermatological Research</i> , 2012, 304, 1-5.	1.1	39
204	A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. <i>British Journal of Dermatology</i> , 2011, 164, no-no.	1.4	28
205	Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. <i>British Journal of Dermatology</i> , 2011, 164, 1-14.	1.4	113
206	Psoriasis comorbidities: a worldwide problem?. <i>British Journal of Dermatology</i> , 2011, 165, 929-929.	1.4	0
207	Whatâ€™s new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010. <i>Clinical and Experimental Dermatology</i> , 2011, 36, 585-589.	0.6	10
208	Re. major life-changing decisions and cumulative life course impairment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 246-246.	1.3	6
209	Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 758-764.	1.3	74
210	Letter from the Editors. <i>Dermatology and Therapy</i> , 2011, 1, 1-1.	1.4	0
211	Evidence to support <i>IL-13</i> as a risk locus for psoriatic arthritis but not psoriasis vulgaris. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1016-1019.	0.5	68
212	Ustekinumab for the treatment of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2011, 7, 155-164.	1.3	9
213	Psoriatic arthritis â€“ what the dermatologist needs to know. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1270-1277.	1.3	18
214	Psoriasis: is the impairment to a patientâ€™s life cumulative?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 989-1004.	1.3	180
215	Systemic therapies containing ethanol and gelatine excipients. <i>British Journal of Dermatology</i> , 2010, 163, 885-886.	1.4	0
216	Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre. <i>British Journal of Dermatology</i> , 2010, 163, 859-862.	1.4	23

#	ARTICLE	IF	CITATIONS
217	What's new in psoriasis? Analysis of the clinical significance of new guidelines and systematic reviews on psoriasis published in 2008 and 2009. <i>Clinical and Experimental Dermatology</i> , 2010, 35, 688-692.	0.6	6
218	A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. <i>Nature Genetics</i> , 2010, 42, 985-990.	9.4	918
219	The use of ustekinumab in autoimmune disease. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 587-604.	1.4	44
220	The Future of Biological Therapies. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 63-66.	1.6	18
221	The Latest Advances in Pharmacogenetics and Pharmacogenomics in the Treatment of Psoriasis. <i>Molecular Diagnosis and Therapy</i> , 2010, 14, 81-93.	1.6	29
222	Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. <i>British Journal of Dermatology</i> , 2009, 160, 162-169.	1.4	48
223	Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. <i>British Journal of Dermatology</i> , 2009, 160, 438-441.	1.4	64
224	Recall injection-site reactions to etanercept in a patient with psoriasis. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 414-415.	0.6	6
225	Long-term control of recalcitrant psoriasis with combination infliximab and methotrexate. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 415-416.	0.6	19
226	What's new in psoriasis? Analysis of the clinical significance of systematic reviews on psoriasis published in 2007 and 2008. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 664-667.	0.6	7
227	Future Therapeutic Directions for the Treatment of Psoriasis. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 28-31.	0.2	1
228	Genetic susceptibility to psoriasis: an emerging picture. <i>Genome Medicine</i> , 2009, 1, 72.	3.6	14
229	Adalimumab for the treatment of psoriasis. <i>Expert Review of Dermatology</i> , 2009, 4, 15-21.	0.3	1
230	Identity of single nucleotide polymorphisms used in a clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy: Comment on the article by Wessels et al. <i>Arthritis and Rheumatism</i> , 2008, 58, 1204-1205.	6.7	0
231	No Association between Polymorphisms in the Interleukin-15 Gene and Early-Onset Psoriasis in a UK Cohort Suggests Heterogeneity for this Susceptibility Locus Identified in Chinese Psoriasis Patients. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2904-2905.	0.3	6
232	Genetic Variation in Efflux Transporters Influences Outcome to Methotrexate Therapy in Patients with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1925-1929.	0.3	109
233	Polymorphisms in the IL-12 β and IL-23R Genes Are Associated with Psoriasis of Early Onset in a UK Cohort. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1325-1327.	0.3	74
234	Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. <i>British Journal of Dermatology</i> , 2008, 158, 962-968.	1.4	41

#	ARTICLE	IF	CITATIONS
235	Methotrexate for psoriasis in the era of biological therapy. <i>Clinical and Experimental Dermatology</i> , 2008, 33, 551-554.	0.6	61
236	Topical Treatments for Scalp Psoriasis. <i>Drugs</i> , 2008, 68, 2293-2302.	4.9	12
237	Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. <i>Clinics in Dermatology</i> , 2008, 26, 438-447.	0.8	67
238	Identification of ZNF313 / RNF114 as a novel psoriasis susceptibility gene. <i>Human Molecular Genetics</i> , 2008, 17, 1938-1945.	1.4	176
239	Precalcaneal Congenital Fibrolipomatous Hamartoma. <i>Pediatric Dermatology</i> , 2007, 24, 74-75.	0.5	15
240	A case of recalcitrant necrobiosis lipoidica responding to combined immunosuppression therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 21, 830-831.	1.3	9
241	Etanercept-induced dermatitis in a patient with rheumatoid arthritis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 614-615.	1.3	12
242	Porokeratotic Eccrine Ostial and Dermal Duct Nevus. <i>Pediatric Dermatology</i> , 2006, 23, 465-466.	0.5	14
243	The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis. <i>British Journal of Dermatology</i> , 2005, 153, 869-873.	1.4	27
244	The effect of the Covid-19 pandemic on illness perceptions of psoriasis and the role of depression: Findings from a cross-sectional study. <i>Skin Health and Disease</i> , 0, , .	0.7	1
245	Associations between psoriatic arthritis and mental health among patients with psoriasis: A replication and extension study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). <i>Skin Health and Disease</i> , 0, , .	0.7	2